Stock Analysis
Royalty Pharma plc Class A Ordinary SharesRPRX
P/E 33.31×· 5Y range 12.63–102.43×· 57th percentile of history
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy16 analystsP/E 33.3× sits at the 57th percentile of its 5.0513347022587265-year history.
Cash covers 9% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Profitability67
Risks
- Growth43
- Financial Health48
Mixed picture — no clear quality or value edge.
Market context
+2.2% today· Z 1.5σ· RVOL 1.9×
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
What's happening with RPRX
Profile
moat, valuation, growth and financial health lag behind.
How is each axis scored?
- Valuation39/100 · Weak
- P/E vs own history (57th pct)12/25
- FCF yield (n/a)10/25
- P/S (10.7x)5/25
- EV/EBIT (23.3x)12/25
- Growth43/100 · Weak
- Revenue CAGR (1.0%)6/25
- Net income CAGR (5.6%)12/25
- EPS CAGR 5Y (-2.2%)0/25
- Fwd implied growth (220.6%)25/25
- Profitability67/100 · Moderate
- ROIC (6.7%)5/25
- ROE (8.3%)12/25
- Net margin (32.1%)25/25
- Operating margin (59.6%)25/25
- Financial Health48/100 · Weak
- Altman Z (2.41)18/25
- Current ratio (2.80)25/25
- Interest coverage (-1.7x)0/25
- Net cash / debt (D/A 41%)5/25
- Quality53/100 · Moderate
- Piotroski F (7/9)22/25
- Beneish M (-3.15)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 23.8%)6/25
- Moat37/100 · Weak
- ROIC >12% years (0/6 yrs)0/25
- Median gross margin (62.9%)25/25
- FCF-positive years (n/a)0/25
- Worst-year net margin (worst 1.9%)12/25
Risk Flags
- ⚠SBC 16.9% of revenue — real dilution cost
- ⚠Interest coverage -1.7× — thin debt cushion
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. Show more
The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Headquarters: NEW YORK, NY · Employees: 100 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
39DP/E (TTM)33.3xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 12.6x–102.4x · 57th pct
P/FCF41.2xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.4%C
Grade C: LowInverse of Finnhub P/FCF (own TTM FCF unavailable)
P/S (TTM)10.70xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 6.4x–13.0x · 78th pct
EV/EBIT23.3xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 12.3x–61.8x · 63rd pct
EV/Sales16.8xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E10.4xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.77xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.89D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield1.16%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio49.0%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
67BROIC6.7%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE8.3%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA4.2%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin32.1%A
Grade A: HighNet Income / Revenue
Operating Margin59.6%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin59.6%A
Grade A: PremiumGross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
43D+Revenue CAGR1.0%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR5.6%C
Grade C: OkCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-2.2%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth220.6%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-26.7%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income52.5%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue16.9%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
48D+Altman Z-Score2.41C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.80xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.80xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-1.7xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT5.4xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.92xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.09xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
53CPiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-3.15A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability23.8%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.13xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Urist Marshall Filed | Urist Marshall | SellOpen market sale | -4126 | |
Hite Christopher Filed | Hite Christopher | SellOpen market sale | -3927 | |
Hite Christopher Filed | Hite Christopher | SellOpen market sale | -96073 | |
Hite Christopher Filed | Hite Christopher | Gift | -16800 | |
Hite Christopher Filed | Hite Christopher | SellOpen market sale | -100000 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Coyne Terrance P. Filed | Coyne Terrance P. | SellOpen market sale | -1772 | |
Coyne Terrance P. Filed | Coyne Terrance P. | SellOpen market sale | -9230 | |
Urist Marshall Filed | Urist Marshall | Gift | -3000 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
37DROIC >12% Years0/6 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)62.9%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years—
Share of completed fiscal years with positive free cash flow
Net Margin Floor1.9%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$1.83
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$1.45
Cash & short-term investments per share (Finnhub)
Book Value / Share$11.87
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$8.96B
Total debt obligations (short + long term)
Cash & Equiv.$836.99M
Cash and short-term investments
Net Debt$8.12B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$9.79B
Shareholders' equity (book value)
Asset / Liability1.98xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$27.14B
Current Market Capitalization
Beta0.39B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: Royalty Pharma plc Class A Ordinary Shares (RPRX)
RPRX is up 2.25% at the last close. Royalty Pharma plc Class A Ordinary Shares meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 2.41 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out.
- Beneish M-Score of -3.15 suggests a low likelihood of earnings manipulation.
- Interest coverage of -1.7× leaves little room for earnings shocks.
See how RPRX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all RPRX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | Regular | 58.90 | +4.12% | 4.42 |
| Oct 14 | After-hours | 59.32 | +4.87% | 5.17 |
| Oct 13 | Regular | 56.55 | -2.13% | -2.50 |
| Oct 13 | After-hours | 56.57 | -2.09% | -2.46 |
| Oct 12 | After-hours | 57.78 | +1.49% | 2.16 |
Frequently Asked Questions about RPRX
What is the current Royalty Pharma plc Class A Ordinary Shares (RPRX) stock price?
RPRX is trading at $60.96 at the last market close, up 2.25% on the session. PreMarketPrice tracks RPRX pre-market, intraday and after-hours prices.
Is RPRX stock a buy right now?
PreMarketPrice's quantitative model rates Royalty Pharma plc Class A Ordinary Shares's financial health at 48/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is RPRX stock overvalued?
Royalty Pharma plc Class A Ordinary Shares trades at a trailing P/E of 33.3 and our valuation score rates it 39/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Royalty Pharma plc Class A Ordinary Shares report earnings?
No confirmed earnings date is currently scheduled for RPRX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Royalty Pharma plc Class A Ordinary Shares operate in?
Royalty Pharma plc Class A Ordinary Shares operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Royalty Pharma plc Class A Ordinary Shares do?
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties.
About Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock
Royalty Pharma plc Class A Ordinary Shares (RPRX) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Royalty Pharma plc Class A Ordinary Shares is trading at $60.96, up 2.25% on the day with a market capitalization of $27.1 billion. The financial health score for RPRX is 48/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for RPRX stock.
RPRX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Royalty Pharma plc Class A Ordinary Shares (RPRX) across multiple dimensions:
- Pre-market price & movement: Real-time RPRX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for RPRX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Royalty Pharma plc Class A Ordinary Shares across multiple reporting periods.
- Financial health score: A composite score of 48/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for RPRX.
- Sector peers: Compare RPRX against 6 other healthcare stocks on key financial metrics.
Is RPRX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Royalty Pharma plc Class A Ordinary Shares (RPRX) as an investment. The financial health score of 48/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Royalty Pharma plc Class A Ordinary Shares (RPRX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.